Greenlight Capital’s Q4 2025 investor letter focuses on a bottom-up portfolio strategy. The Partnership returned 9.0% in 2025 and 8.5% in Q4, compared to the S&P 500 index. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is highlighted as a top pick, with a one-month return of 7.08% and a market capitalization of $36.63 billion.

Greenlight Capital notes Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) rapid growth in its branded portfolio. The company’s progress in transitioning to a branded pharmaceutical company has led to positive market developments, including a pricing agreement with the Centers for Medicare & Medicaid Services for its drug Austedo starting in 2027.

While Teva Pharmaceutical Industries Limited (NYSE:TEVA) is not among the 30 most popular stocks among hedge funds, 60 hedge fund portfolios held the stock in Q3. The company offers investment potential, but certain AI stocks may have greater upside and less downside risk. For more information on a highly undervalued AI stock, see the free report on the best short-term AI stock.

Read more at Yahoo Finance: What Makes Teva Pharmaceuticals (TEVA) a Successful Brand?